Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study
Adam S. Kittai(Icahn School of Medicine at Mount Sinai), Philip A. Thompson(The Royal Melbourne Hospital), Levanto Schachter(Oregon Health & Science University), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Mark R. Dowling(The Royal Melbourne Hospital), Nitin Jain(Parul University), Deborah M. Stephens(University of North Carolina at Chapel Hill), Emily Blyth(Westmead Hospital), Caron A. Jacobson(Dana-Farber Cancer Institute), Aditi Saha(Moffitt Cancer Center), Caitlyn Duffy(Harvard University), Kerry A. Rogers(The Ohio State University), Erin M. Parry(Broad Institute), Seema A. Bhat(The Ohio State University), Mazyar Shadman(University of Washington), David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Christine McCarthy(City Of Hope National Medical Center), P Manoj(Oregon Health & Science University), Matthew S. Davids(Dana-Farber Cancer Institute), Hamish W Scott(St Vincent’s Private Hospital Sydney), Samantha Jaglowski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Vinay Vanguru(Royal Prince Alfred Hospital), Jayastu Senapati(The University of Texas MD Anderson Cancer Center), Ying Huang(Linyi University), Julio C. Chávez(Moffitt Cancer Center), Zulfa Omer(University of Cincinnati), Carrie Ho(University of California, San Francisco), Cecelia Miller, William G. Wierda(University of Maryland, Baltimore), Kevin H. Lin(Harvard University), John C. Byrd(University of Cincinnati), Jamie P Dela Cruz(Harvard University), Tanya Siddiqi(City Of Hope National Medical Center)
Cited by 43
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k